Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00288392
Recruitment Status : Completed
First Posted : February 8, 2006
Last Update Posted : October 18, 2006
Information provided by:
Biotec Pharmacon ASA

Brief Summary:

The purpose of this study is to evaluate the efficacy of soluble beta-1,3/1,6-glucan compared to placebo on the healing of chronic leg ulcers in diabetes patients.

Hypothesis: Through its ability to activate tissue macrophages and counteract diabetes-associated defects in macrophages, the soluble beta-1,3/1,6-glucan will promote the healing of leg ulcers in diabetic patients.

Condition or disease Intervention/treatment Phase
Foot Ulcer Drug: Soluble beta-1,3/1,6-glucan Phase 2

Detailed Description:

Diabetes predisposes to ulceration of the foot through a variety of processes, including neuropathy and peripheral arterial disease. Once the skin is broken, healing is frequently delayed and the ulcer develops the biology of a chronic wound. The factors underlaying delayed healing in chronic wounds are not well understood but include the effects of repeated trauma, tissue ischemia, infection, defective white cell function, altered immune processes, and altered expression of tissue cytokines and enzymes.

Management is based on regular cleansing and debridement, off-loading and treatment of intercurrent infection with antibiotics. There are no interventions in routine use, which target aspects of chronic wound biology directly.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind Therapeutic Exploratory Clinical Study to Evaluate the Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients
Study Start Date : June 2005
Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. - Time to healing

Secondary Outcome Measures :
  1. Number of patients with complete healing of treated ulcers after 12 weeks of treatment
  2. Percentage reduction in ulcer area of treated ulcers after 12 weeks of treatment
  3. Percentage weekly reduction in ulcer area in treated ulcers
  4. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 or Type 2 diabetes mellitus
  • Age>= 18 years
  • Study wound is a Wagner Grade 1 partial thickness or Grade 2 full thickness lesion but without exposed tendon, joint, or bones
  • Study wound located on the foot or lower leg
  • Study wound must have been present for at least 4 weeks prior to Day 0 but not longer than 2 years
  • Adequate circulation to the foot, evidenced by a palpable pulse on the study foot
  • Study wound > 1.0cm2 but < 20.0cm2
  • Written informed consent

Exclusion Criteria:

  • Pregnancy, lactation or absence of adequate contraception for fertile women
  • Ankle/Brachial Index < 0.7
  • Severe malnutrition
  • Clinical evidence of gangrene on any part of the foot with the study wound
  • Active or extensive cellulitis extending more than 1 cm beyond wound margin and/or presence of cellulitis with purulent discharge on day 0
  • One or more medical condition(s) that in the opinion of the investigator would make the patient an inappropriate candidate for the study
  • Active osteomyelitis of the foot with the study wound
  • Necrotic toes on the foot with the study wound
  • Surgical procedure (other than debridement) on the foot with the study wound the last 21 days prior to screening
  • Study wound over a Charcot's joint
  • Evidence of deep tissue infection of the study wound at day 0
  • Non-study wound on the study foot that is located within 5.0cm from the study wound at day 0
  • Random blood sugar reading > 450 mg/dL
  • Alcohol or drug abuse
  • Participation in other clinical studies in the last 4 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00288392

Layout table for location information
Russian Federation
Municipal Healthcare Institution 1st City Clinical Hospital
Arkhangelsk, Russian Federation, 163061
St. Petersburg State Institution Saint Martyr Elezabeth Hospital
St. Petersburg, Russian Federation, 195257
Sponsors and Collaborators
Biotec Pharmacon ASA
Layout table for investigator information
Principal Investigator: Tatyana Zykova, Municipal Healthcare Institution 1st City Hospital, Department of Endocrinology

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00288392    
Other Study ID Numbers: SBG-1-11
First Posted: February 8, 2006    Key Record Dates
Last Update Posted: October 18, 2006
Last Verified: May 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Foot Ulcer
Leg Ulcer
Pathologic Processes
Foot Diseases
Skin Diseases
Skin Ulcer